TY - JOUR
T1 - Emerging chelators for nuclear imaging
AU - Sneddon, Deborah
AU - Cornelissen, Bart
N1 - Funding Information:
As this field is continually developing, the authors regret that some work published after beginning this manuscript was unable to be included. In addition, owing to size limitations, not all details have been included for the chelators discussed. The authors would like to thank Julia Baguña Torres and Stephen Faulkner. This work was supported by Cancer Research, UK , through the Oxford Institute for Radiation Oncology.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/8
Y1 - 2021/8
N2 - Chelators are necessary in nuclear medicine imaging to direct an inorganic radionuclide, a radiometal, to a desired target; unfortunately, there is no ‘one-size-fits-all’ chelator. As the toolbox of radiometals is expanding, new chelators are required to prevent off-target side effects. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is the current gold standard chelator for several radiometals, but typically, chelation requires harsh conditions, making it unsuitable to label biological vectors. The ideal chelator would allow labelling under mild conditions (near-neutral pH and low temperatures [∼37 °C]) and be both thermodynamically and kinetically stable. Over the past 2–3 years, several exciting chelators have been developed that have superior properties to make them worth investigating for future clinical applications.
AB - Chelators are necessary in nuclear medicine imaging to direct an inorganic radionuclide, a radiometal, to a desired target; unfortunately, there is no ‘one-size-fits-all’ chelator. As the toolbox of radiometals is expanding, new chelators are required to prevent off-target side effects. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is the current gold standard chelator for several radiometals, but typically, chelation requires harsh conditions, making it unsuitable to label biological vectors. The ideal chelator would allow labelling under mild conditions (near-neutral pH and low temperatures [∼37 °C]) and be both thermodynamically and kinetically stable. Over the past 2–3 years, several exciting chelators have been developed that have superior properties to make them worth investigating for future clinical applications.
KW - Lutetium-177 radiopharmaceutical
KW - PET
KW - Scandium-44
KW - Zirconium-89
U2 - 10.1016/j.cbpa.2021.03.001
DO - 10.1016/j.cbpa.2021.03.001
M3 - Review article
C2 - 34051509
AN - SCOPUS:85106945676
SN - 1367-5931
VL - 63
SP - 152
EP - 162
JO - Current Opinion in Chemical Biology
JF - Current Opinion in Chemical Biology
ER -